Media stories about BIO-TECHNE (NASDAQ:TECH) have been trending somewhat positive on Wednesday, according to Accern Sentiment. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. BIO-TECHNE earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.7076191496175 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Shares of BIO-TECHNE (TECH) traded up $0.26 on Wednesday, reaching $146.82. The company’s stock had a trading volume of 110,886 shares, compared to its average volume of 186,340. BIO-TECHNE has a 12 month low of $98.22 and a 12 month high of $148.26. The stock has a market cap of $5,497.06, a price-to-earnings ratio of 48.14, a PEG ratio of 2.81 and a beta of 0.75. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.10 and a quick ratio of 2.49.
BIO-TECHNE (NASDAQ:TECH) last announced its quarterly earnings results on Tuesday, February 6th. The biotechnology company reported $1.02 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.92 by $0.10. The business had revenue of $154.15 million for the quarter, compared to analyst estimates of $145.93 million. BIO-TECHNE had a return on equity of 14.39% and a net margin of 19.17%. The company’s quarterly revenue was up 16.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.81 EPS. equities analysts predict that BIO-TECHNE will post 4.01 EPS for the current fiscal year.
Several equities analysts recently issued reports on TECH shares. Zacks Investment Research cut BIO-TECHNE from a “buy” rating to a “hold” rating in a research report on Tuesday, December 19th. BidaskClub cut BIO-TECHNE from a “buy” rating to a “hold” rating in a research report on Tuesday, December 5th. Leerink Swann restated a “buy” rating on shares of BIO-TECHNE in a research report on Tuesday, December 5th. Robert W. Baird restated a “buy” rating and issued a $154.00 price target on shares of BIO-TECHNE in a research report on Thursday, January 18th. Finally, Craig Hallum restated a “buy” rating and issued a $160.00 price target (up previously from $140.00) on shares of BIO-TECHNE in a research report on Wednesday, February 7th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $148.60.
In other news, Director Charles A. Dinarello sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $136.06, for a total transaction of $680,300.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 3.40% of the stock is owned by insiders.
TRADEMARK VIOLATION WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact BIO-TECHNE (TECH) Share Price” was originally posted by BBNS and is owned by of BBNS. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://baseballnewssource.com/2018/03/14/bio-techne-tech-given-media-impact-score-of-0-18/1927559.html.
BIO-TECHNE Company Profile
Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.
Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with MarketBeat.com's FREE daily email newsletter.